TY - JOUR T1 - Quality of life assessment in advanced stage of lung cancer patients before and after chemotherapy JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA4650 VL - 54 IS - suppl 63 SP - PA4650 AU - Ram Niwas AU - Jagdish Chander Suri AU - Shibdas Chakrabarti AU - Manas Kamal Sen AU - Rajani Kumawat AU - Gopal Chawla Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA4650.abstract N2 - Background: In India, there have been few studies discussing the QOL in lung cancer and work published from developed countries do not reflect the true context of Indian patients.Material and Method: 165 confirmed cases of advanced lung cancer, scheduled for chemotherapy, were enrolled prospectively. The information about QOL of patients was collected before and after chemotherapy, using the EORTC core questionnaire (QLQ C-30 Version 3) and lung cancer module (LC-13) and analyzed as recommended by the EORTC.Results: Mean age of the study group was 54.3 with male to female ratio of 2.8. Of all patients, 156 cases completed the assessment after chemotherapy. The significantly changed quality of life scores amongst EORTC QLQ C30 & LC13 items after chemotherapy are shown in the Table 1. On subgroups analysis between conventional chemotherapy and TKIs, vomiting and hemoptysis score(p =.00) were significantly better with TKIs.Conclusion: This study suggest that chemotherapy may improve QOL in lung cancer patients and using questionnaires to assess the QOL during treatment helps in identifying changes of the QOL and adverse effects of therapy.View this table:TableĀ 1. QOL items with significant changes after chemotherapy.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4650.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -